Your SlideShare is downloading. ×
Japan pharmaceutical market outlook   deregulation and more efficient new drug approval process attract foreign investment - Reports Corner
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Japan pharmaceutical market outlook deregulation and more efficient new drug approval process attract foreign investment - Reports Corner


Published on

GBI Research, the leading business intelligence provider, has released its latest research “Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract …

GBI Research, the leading business intelligence provider, has released its latest research “Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players”. Japan’s pharmaceutical industry is the second largest in the world, worth $89 billion in 2011 or 10% of the world market.

Published in: News & Politics, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. RCReports CornerJapan Pharmaceutical Market Outlook - Deregulation and More EfficientNew Drug Approval Process Attract Foreign Investment and Improve theCompetitiveness of Japanese Players
  • 2. DescriptionDescriptionReports Cornerwww.reportscorner.comGBI Research, the leading business intelligence provider, hasreleased its latest research “Japan Pharmaceutical MarketOutlook - Deregulation and More Efficient New Drug ApprovalProcess Attract Foreign Investment and Improve theCompetitiveness of Japanese Players”. Japan’s pharmaceuticalindustry is the second largest in the world, worth $89 billion in2011 or 10% of the world market.
  • 3. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThe Declining and Rapidly Aging Population Presents SignificantChallenges to the Healthcare System and Economy as aWholeJapan had a population of 127,817,277 in 2011, making it the10th most populated country in the world (The World Bank, 2012).However, since 2005, as the number of deaths exceeded that ofbirths, the population has declined. Without significantgovernment intervention, the depopulation process is expected tocontinue.The proportion of people aged 65 or over is 23.3% andprojected to reach 29.1% by 2020 and almost 40% by 2050(Statistical Research and Training Institute, 2012).Thesedemographic changes will present further challenges to astagnating economy, which, as the data in this report confirms, isalready struggling with reduced economic growth. A diminishingworkforce and falling productivity levels will likely add to theeconomic difficulties Japan is experiencing.
  • 4. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comThe associated increase in disease burden has also hadimplications for the healthcare system. Healthcare expenditurehas risen, and is set to rise further as the population continues toage.In 2010, Japan’s healthcare spending per capita was $4,065.4,a significant increase from 2005.Japan’s universal healthcaresystem may therefore prove unsustainable as the governmentlooks to control spending. A combination of pro-generic policies,government initiatives to prevent lifestyle diseases, and highercopayments should help to keep healthcare expenditure undercontrol.Regulatory Reform will Continue to Attract ForeignPharmaceutical CompaniesThe ongoing deregulation of theJapanese pharmaceutical industry has made it an attractivemarket for big pharma. Improvements to the new drug approvalprocess have significantly shortened the approval time.Consultation services provided by approval bodies have beenexpanded and improved, approval standards have been clarified
  • 5. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comand the number of trained personnel involved in the reviewprocess has increased.Many of these changes have occurredfollowing the introduction of a number of plans and governmentpolicies. Plans are currently being implemented to shorten thereview period and improve cooperation with other countries,particularly Western and other Asian nations, such as the SecondMedium Range Plan (2009–2014), which includes the InternationalStrategic Plan.In April 2007, the government introduced the 5-YearStrategy for the Creation of Innovative Pharmaceuticals andMedical Devices, which contributed towards the reduction in lagtime associated with new product approvals.In addition toattracting foreign investment, deregulation has also improved thecompetitiveness of Japan’s pharmaceutical companies. Themarket now consists of multinational players such as Takeda andDaiichi Sankyo, who market leading products globally. TakedaMaintains its Position as the Leading Company in the JapanesePharmaceutical
  • 6. Brief SummaryBrief SummaryReports Cornerwww.reportscorner.comIndustryTakeda maintained its position as the leader in Japan’spharmaceutical industry in 2012, with revenues of $18.9 billion.This was followed by Otsuka Holdings, Astellas, Daiichi Sankyoand Eisai.M&A activity has become a common theme within theglobal pharmaceutical industry. This is often a strategic responseto patent expirations, reduced R&D productivity and the need tocut costs.The Japanese pharmaceutical industry has followed thistrend. Although historically dependent on domestic R&D, therecent globalization of Japanese companies has been driven byenhanced M&A activity. Significant deals have been completed inthe US, Europe and developing nations, such as China, India andBrazil.With a total of 20 M&A, including two recently announced,Takeda has been the most active Japanese company.The M&Astrategy is seen as necessary for pharmaceutical companies keento expand product pipelines following patent expirations and gainaccess to untapped markets. It is hoped that such strategicmeasures will help develop or maintain growth and revenue.
  • 7. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com1 Table of Contents1 Table of Contents 61.1 List of Tables 81.2 List of Figures 82 Introduction 103 Market Overview 113.1 Introduction 113.2 Economic Landscape 113.3 Economic Indicators 123.3.1 Gross Domestic Product 123.3.2 GDP Composition by Sector 153.3.3 Consumer Price Index 163.3.4 Unemployment 183.3.5 Exchange Rate 203.3.6 Foreign Direct Investment 21
  • 8. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com3.3.7 Trade Balance 233.3.8 Value of Exports/Imports 243.3.9 Exports and Imports Forecast 253.3.10 Trading Partners 263.3.11 Government Debt 273.3.12 Gross National Income 283.3.13 Gross National Savings 313.3.14 Labor Force 323.3.15 Employment 343.3.16 Current Account Balance 363.3.17 Foreign Exchange Reserves 373.4 Demographic Analysis 383.4.1 Population 383.4.2 Population Distribution 393.4.3 Urban-Rural Share 40
  • 9. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com3.5 Healthcare 413.5.1 Healthcare Expenditure 413.5.2 Public and Private Expenditure 433.5.3 Healthcare Infrastructure 463.5.4 Alcohol Consumption 493.5.5 Tobacco Consumption 503.5.6 Obesity 523.5.7 Life Expectancy 533.5.8 Leading Causes of Death 543.5.9 Pharmaceutical Expenditure 553.5.10 Insurance and Reimbursement 553.5.11 Reimbursement Process 573.6 Market Segments 583.6.1 Generics 583.6.2 Over-the-Counter Drugs 59
  • 10. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com4 Industry Characteristics 604.1 Introduction 604.2 Pricing Policy 604.2.1 Reimbursement Prices for New Drugs 604.3 Regulatory Landscape 624.3.1 Pharmaceutical and Food Safety Bureau 644.3.2 Pharmaceutical and Medical Devices Agency 654.3.3 New Drug Approval Process 664.3.4 Drug Manufacture 684.3.5 Clinical Trials – Basic Requirements 684.3.6 Advertising 684.3.7 Licensing 694.3.8 Orphan Drugs 694.4 Pharmaceutical Supply Chain 704.4.1 Leading Companies 71
  • 11. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com5 Competitive Landscape 725.1 Introduction 725.2 Major Domestic Companies 725.2.1 Major Players by Revenue 725.2.2 Takeda 735.2.3 Product Portfolio 735.2.4 Research and Development 735.2.5 Otsuka 765.2.6 Product Portfolio 765.2.7 Research and Development 775.2.8 Astellas 785.2.9 Product Portfolio 795.2.10 Research and Development 805.2.11 Daiichi Sankyo 815.2.12 Product Portfolio 81
  • 12. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com5.2.13 Research and Development 825.2.14 Eisai 835.2.15 Research and Development 845.3 Major Foreign Players 855.4 Acquisitions and Collaboration 865.4.1 M&A 865.4.2 Licensing Agreements and Co-development Deals 896 Drivers and Barriers 926.1 Drivers 926.1.1 World-Leading Life Expectancy – Increased Disease Burden 926.1.2 Deregulation – Easing of Regulatory Guidelines 926.1.3 Government Initiatives to Prevent Lifestyle Diseases 926.1.4 Continued Growth of the Generics Market 926.2 Barriers 936.2.1 Time Lag in Drug Approval Process 93
  • 13. Table of ContentsTable of ContentsReports Cornerwww.reportscorner.com6.2.2 Political Instability 936.2.3 High Cost of Clinical Trials 936.2.4 High Value of the Yen 937 Japan Pharmaceutical Market Outlook – Appendix 947.1 Market Definitions 947.2 Abbreviations 947.3 Bibliography 957.4 Research Methodology 967.5 Coverage 967.6 Secondary Research 977.7 Competitive Landscape 977.7.1 Expert Panel Validation 977.8 Contact Us 977.9 Disclaimer 97
  • 14. For more informationFor more informationReports Cornerwww.reportscorner.comFor more information please visit our website
  • 15. Reports CornerThank YouThank Youwww.reportscorner.comRCContact us: